Study to Investigate the Safety and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects

A Dose Blocked-randomized, Double-blind, Placebo-controlled, Single Dosing and Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects

To investigate the safety, tolerability and pharmacokinetic characteristics of LC28-0126 in healthy male subjects

Inclusion Criteria:

• Healthy male subjects between the ages of 20 and 45 years at screening.
• Subjects with BMI between 18.0(inclusive) and 27.0 kg/m2 (exclusive); and a total body weight between 55 kg (inclusive) and 90 kg (exclusive)

Exclusion Criteria:

• Participation in a clinical research study within the previous 2 months
• Regular alcohol consumption >21 units per week.